Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies.
Neisseria meningitidis
conjugate vaccine
immunization strategies
serogroup A
Journal
Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
24
4
2020
medline:
17
3
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
For well over 100 years, meningococcal disease due to serogroup A The article reviews the background and identification of MenA, the global and molecular epidemiology of MenA, and the outbreaks of MenA in the African meningitis belt. The implementation (2010) of an equitable MenA polysaccharide-protein conjugate vaccine (Ps Using strategies from the successful MenAfriVac campaign, expanded collaborative partnerships were built to develop a novel, low-cost multivalent component meningococcal vaccine that includes MenA. This vaccine promises greater sustainability and is directed toward global control of meningococcal disease in the African meningitidis belt and beyond. The new WHO global roadmap addresses the continuing problem of bacterial meningitis, including meningococcal vaccine prevention, and provides a framework for further reducing the devastation of MenA.
Identifiants
pubmed: 32321332
doi: 10.1080/14760584.2020.1760097
pmc: PMC8214415
mid: NIHMS1600416
doi:
Substances chimiques
MenAfriVac
0
Meningococcal Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
455-463Subventions
Organisme : NIAID NIH HHS
ID : T32 AI074492
Pays : United States
Références
Epidemiol Infect. 1987 Dec;99(3):591-601
pubmed: 3123263
Epidemiol Infect. 2006 Jun;134(3):556-66
pubmed: 16238823
Mol Microbiol. 1997 Sep;25(6):1047-64
pubmed: 9350862
Wkly Epidemiol Rec. 1997 Oct 17;72(42):313-8
pubmed: 9347699
J Infect Dis. 1998 Aug;178(2):451-9
pubmed: 9697726
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):271-6
pubmed: 8990198
Rev Infect Dis. 1987 Jul-Aug;9(4):665-92
pubmed: 3125576
Vaccine. 2007 Sep 3;25 Suppl 1:A97-100
pubmed: 17521780
Commun Dis Public Health. 2002 Sep;5(3):220-5
pubmed: 12434692
J Bacteriol. 1998 Mar;180(6):1533-9
pubmed: 9515923
Lancet. 2007 Jun 30;369(9580):2196-2210
pubmed: 17604802
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5
pubmed: 9501229
Vaccine. 2013 Jun 7;31(25):2731-7
pubmed: 23588082
Lancet. 2014 Jan 4;383(9911):40-47
pubmed: 24035220
Vaccine. 2014 Mar 14;32(13):1431-5
pubmed: 24559895
Scand J Infect Dis. 1992;24(3):323-32
pubmed: 1324522
J Exp Med. 1969 Jun 1;129(6):1349-65
pubmed: 4977282
Lancet. 1999 Mar 20;353(9157):941-2
pubmed: 10459897
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S521-30
pubmed: 26553684
Health Aff (Millwood). 2011 Jun;30(6):1049-57
pubmed: 21653956
Vaccines (Basel). 2018 Feb 25;6(1):
pubmed: 29495347
Infect Immun. 1992 Dec;60(12):5267-82
pubmed: 1452360
Clin Infect Dis. 2013 Feb;56(3):354-63
pubmed: 23087396
Bull World Health Organ. 1971;45(1):95-101
pubmed: 5316855
J Infect. 2018 May;76(5):429-437
pubmed: 29406154
N Engl J Med. 2001 May 3;344(18):1378-88
pubmed: 11333996
Epidemiol Infect. 1995 Dec;115(3):399-409
pubmed: 8557071
Vaccine. 2009 Jan 29;27(5):726-32
pubmed: 19063929
Lancet. 2003 May 31;361(9372):1902-4
pubmed: 12788589
Lancet Infect Dis. 2018 Oct;18(10):1088-1096
pubmed: 30120069
J Infect Dis. 2010 Apr 15;201(8):1208-24
pubmed: 20199241
Lancet Infect Dis. 2017 Aug;17(8):867-872
pubmed: 28545721
Vaccine. 2009 Jun 24;27 Suppl 2:B51-63
pubmed: 19477562
Infect Immun. 2003 Dec;71(12):6712-20
pubmed: 14638755
Emerg Infect Dis. 2003 Oct;9(10):1287-93
pubmed: 14609465